FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAgomAb Therapeutics N.V. American Depositary Shares
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGMB
AgomAb Therapeutics N.V. American Depositary Shares Stock AnalysisComprehensive stock analysis for AgomAb Therapeutics N.V. American Depositary Shares (AGMB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAGMB
AGMB
AgomAb Therapeutics N.V. American Depositary Shares
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGMB
  1. Home
  2. Stocks
  3. AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. American Depositary Shares

🇺🇸AGMB•NASDAQ

AgomAb Therapeutics N.V. American Depositary Shares

🇺🇸AGMB•NASDAQ
Market cap
$286.62M

Your view on AGMB

Mkt Cap
$286.62M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About AgomAb Therapeutics N.V. American Depositary Shares

Industry
Biotechnology
Sector
Healthcare
CEO
Tim Knotnerus
Headquarters
Posthoflei 1/6, Antwerp, VL, BE
Industry
Biotechnology
Sector
Healthcare
CEO
Tim Knotnerus
Headquarters
Posthoflei 1/6, Antwerp, VL, BE
Description

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist.

Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials.

Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF.

This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for AgomAb Therapeutics N.V. American Depositary Shares. Starting points for AgomAb Therapeutics N.V. American Depositary Shares: EPS -$0.73, beta 1.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for AgomAb Therapeutics N.V. American Depositary Shares. Trailing twelve-month EPS for AgomAb Therapeutics N.V. American Depositary Shares stands at -$0.73. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' targetEUR 35.00average of analysts' targets
Current price—

Targets, low to high

$35.00

Low $35.00

Middle $35.00

High $35.00

More →

Earnings per share estimates

Per shareThis quarterMar 2026Next quarterJun 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateEUR 1.18−EUR 0.96−EUR 1.71−EUR 2.01
Lowest estimateEUR 1.04−EUR 1.04−EUR 2.02−EUR 2.62
Highest estimateEUR 1.29−EUR 0.91−EUR 1.36−EUR 1.33
Number of analysts2266
A year ago——−EUR 1.28—
Growth vs a year ago——−33.7%—

Revenue estimates

TotalThis quarterMar 2026Next quarterJun 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateEUR 0.00EUR 0.00EUR 505517.00EUR 606625.00
Lowest estimateEUR 0.00EUR 0.00EUR 505517.00EUR 606625.00
Highest estimateEUR 0.00EUR 0.00EUR 505517.00EUR 606625.00
Number of analysts0066
A year ago——EUR 0.00—
Growth vs a year ago————
Recent rating and target changes (1)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for AgomAb Therapeutics N.V. American Depositary Shares. AgomAb Therapeutics N.V. American Depositary Shares has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AGMB17 companies · 1 funds
Compare AGMB with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACRSAclaris Therapeutics, Inc.HealthcareBiotechnology$555.1M
ALMSAlumis Inc. Common StockHealthcareBiotechnology$568.9M
ANABAnaptysBio, Inc.HealthcareBiotechnology$1.4B
EQEquillium, Inc.HealthcareBiotechnology$90.6M
ODTXOdyssey Therapeutics, Inc.HealthcareBiotechnology$912.3M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PTCHFPureTech Health plcHealthcareOTC$410.4M
PTCTPTC Therapeutics, Inc.HealthcareNASDAQ$5.0B
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$8.3B
PTHSPelthos Therapeutics Inc.HealthcareAMEX$27.9M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$9.2M
PTX.AXPrescient Therapeutics LimitedHealthcareASX—
PULMPulmatrix, Inc.HealthcareNASDAQ$4.9M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareOTC$18.7M
PVLAPalvella Therapeutics, Inc.HealthcareNASDAQ$2.1B
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
PXXLFPoxel S.A.HealthcareOTC$13.4M
ETFs holding AgomAb Therapeutics N.V. American Depositary Shares
TickerFundFund assets% of the fund
SBIOALPS Medical Breakthroughs ETF$187M in assets0.19%

Largest holders first, then the funds most concentrated in AGMB.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold AgomAb Therapeutics N.V. American Depositary Shares, and how their positions are changing. At a $286.6M market value, institutional positions materially move AgomAb Therapeutics N.V. American Depositary Shares's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by AgomAb Therapeutics N.V. American Depositary Shares executives and directors. Shares of AgomAb Therapeutics N.V. American Depositary Shares have traded between $8.75 and $17.82 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for AgomAb Therapeutics N.V. American Depositary Shares. Coverage tracks AgomAb Therapeutics N.V. American Depositary Shares within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of AgomAb Therapeutics N.V. American Depositary Shares.

AGMB AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1